1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gastrointestinal Bleeding Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gastrointestinal Bleeding Treatment Market, by Treatment Modality
8.1.1. Endoscopic Hemostasis Devices and Accessories
8.1.1.1. Market Revenue and Forecast
8.1.2. Pharmaceutical Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Embolization and Interventional Radiology
8.1.3.1. Market Revenue and Forecast
8.1.4. Surgical Interventions
8.1.4.1. Market Revenue and Forecast
8.1.5. Other Adjunct Therapies
8.1.5.1. Market Revenue and Forecast
9.1. Gastrointestinal Bleeding Treatment Market, by Endoscopy Type
9.1.1. Upper GI Endoscopy Treatments
9.1.1.1. Market Revenue and Forecast
9.1.2. Lower GI Endoscopy Treatments
9.1.2.1. Market Revenue and Forecast
10.1. Gastrointestinal Bleeding Treatment Market, by Drug Category
10.1.1. Proton Pump Inhibitors
10.1.1.1. Market Revenue and Forecast
10.1.2. Vasoactive Agents
10.1.2.1. Market Revenue and Forecast
10.1.3. Antifibrinolytic Drugs
10.1.3.1. Market Revenue and Forecast
10.1.4. Others (e.g., mucosal protective agents)
10.1.4.1. Market Revenue and Forecast
11.1. Gastrointestinal Bleeding Treatment Market, by End User
11.1.1. Hospitals and Specialty Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Ambulatory Surgery Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Diagnostic and Imaging Centers
11.1.3.1. Market Revenue and Forecast
11.1.4. Others (Private Practices, Homecare)
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Modality
12.1.2. Market Revenue and Forecast, by Endoscopy Type
12.1.3. Market Revenue and Forecast, by Drug Category
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Treatment Modality
12.1.5.2. Market Revenue and Forecast, by Endoscopy Type
12.1.5.3. Market Revenue and Forecast, by Drug Category
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Treatment Modality
12.1.6.2. Market Revenue and Forecast, by Endoscopy Type
12.1.6.3. Market Revenue and Forecast, by Drug Category
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Modality
12.2.2. Market Revenue and Forecast, by Endoscopy Type
12.2.3. Market Revenue and Forecast, by Drug Category
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Treatment Modality
12.2.5.2. Market Revenue and Forecast, by Endoscopy Type
12.2.5.3. Market Revenue and Forecast, by Drug Category
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Treatment Modality
12.2.6.2. Market Revenue and Forecast, by Endoscopy Type
12.2.6.3. Market Revenue and Forecast, by Drug Category
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Treatment Modality
12.2.7.2. Market Revenue and Forecast, by Endoscopy Type
12.2.7.3. Market Revenue and Forecast, by Drug Category
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Treatment Modality
12.2.8.2. Market Revenue and Forecast, by Endoscopy Type
12.2.8.3. Market Revenue and Forecast, by Drug Category
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Modality
12.3.2. Market Revenue and Forecast, by Endoscopy Type
12.3.3. Market Revenue and Forecast, by Drug Category
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Treatment Modality
12.3.5.2. Market Revenue and Forecast, by Endoscopy Type
12.3.5.3. Market Revenue and Forecast, by Drug Category
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Treatment Modality
12.3.6.2. Market Revenue and Forecast, by Endoscopy Type
12.3.6.3. Market Revenue and Forecast, by Drug Category
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Treatment Modality
12.3.7.2. Market Revenue and Forecast, by Endoscopy Type
12.3.7.3. Market Revenue and Forecast, by Drug Category
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Treatment Modality
12.3.8.2. Market Revenue and Forecast, by Endoscopy Type
12.3.8.3. Market Revenue and Forecast, by Drug Category
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Modality
12.4.2. Market Revenue and Forecast, by Endoscopy Type
12.4.3. Market Revenue and Forecast, by Drug Category
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Treatment Modality
12.4.5.2. Market Revenue and Forecast, by Endoscopy Type
12.4.5.3. Market Revenue and Forecast, by Drug Category
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Treatment Modality
12.4.6.2. Market Revenue and Forecast, by Endoscopy Type
12.4.6.3. Market Revenue and Forecast, by Drug Category
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Modality
12.4.7.2. Market Revenue and Forecast, by Endoscopy Type
12.4.7.3. Market Revenue and Forecast, by Drug Category
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Treatment Modality
12.4.8.2. Market Revenue and Forecast, by Endoscopy Type
12.4.8.3. Market Revenue and Forecast, by Drug Category
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Modality
12.5.2. Market Revenue and Forecast, by Endoscopy Type
12.5.3. Market Revenue and Forecast, by Drug Category
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Treatment Modality
12.5.5.2. Market Revenue and Forecast, by Endoscopy Type
12.5.5.3. Market Revenue and Forecast, by Drug Category
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Treatment Modality
12.5.6.2. Market Revenue and Forecast, by Endoscopy Type
12.5.6.3. Market Revenue and Forecast, by Drug Category
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Boston Scientific Corporation
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. CONMED Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Cook Group
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ERBE Elektromedizin GmbH
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Medtronic PLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Olympus Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Ovesco Endoscopy AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. STERIS PLC
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. US Medical Innovations
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
